In this investigation, we unveiled a new mechanism underlying the tumor-promoting effect of MC-LR in TME and highlight the potential of targeting the MC-LR/M2-TAM/TGF-β1/CST3 axis as a therapeutic strategy for CRC (Figure 5). The gene discussed is CST3; the disease is neoplasm.